Clinical review: Immunomodulatory effects of dopamine in general inflammation

Critical Care

Volumn 8, Issue 6, 2004, Pages 485-491

  Beck, Grietje Ch ^a   Brinkkoetter, Paul ^a   Hanusch, Christine ^a   Schulte, Jutta ^a   van Ackern, Klaus ^a   van der Woude, Fokko J ^a   Yard, Benito A ^a  

^a UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

Adhesion molecules; Cytokines; Dopamine; Hemostatis; Sepsis

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ANTIBIOTIC AGENT; AUTACOID; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; CD11B ANTIGEN; CD18 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GROWTH HORMONE; HYDROCORTISONE; HYPERTENSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; NITRIC OXIDE; PROLACTIN; THYROID HORMONE; VASOACTIVE AGENT;

ADRENERGIC SYSTEM; APOPTOSIS; BLOOD PRESSURE REGULATION; CATECHOLAMINE RELEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; FLUID THERAPY; HEART MUSCLE BLOOD FLOW; HORMONE DEFICIENCY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; NEUROENDOCRINOLOGY; NEUTROPHIL CHEMOTAXIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEPSIS; T LYMPHOCYTE; TISSUE PERFUSION; VASODILATATION;

CATECHOLAMINES; CYTOKINES; DOPAMINE; ENDOTOXEMIA; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; SHOCK, SEPTIC; SYMPATHETIC NERVOUS SYSTEM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11344254379     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc2879     Document Type: Review

References (69)

1. Bergmann M, Sautner T: Immunomodulatory effects of vasoactive catecholamines. Wien Klin Wochenschr 2002, 114: 52-761.
2. Pastores SM, Hasko G, Vizi ES, Kvetan V: Cytokine production and its manipulation by vasoactive drugs. New Horiz 1996, 4: 252-264.
3. Barnes PJ: Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1999, 152:838-860.
4. Braunstein KM, Arji KE, Kleinfelder J, Schraibman HB, Colwell JA, Eurenius K: The effects of dopamine on human platelet aggregation in vitro. J Pharmacol Exp Ther 1977, 200:449-475.
5. McDonald RH, Goldberg LI, McNay JL, Tuttle NP: Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 1964, 43: 116-1124.
6. Vincent JL, de Backer D: The International sepsis forum's controversies in sepsis: my initial vasopressor agent in septic shock is dopamine rather than norepinephrine. Crit Care 2003, 7: -8.
7. Girbes AR, Lieverse AG, Smit AJ: Lack of specific renal haemodynamic effects of different doses of dopamine after infrarenal aortic surgery. Br J Anaesth 1996, 77:753-757.
8. Meier-Hellmann A, Reinhart K: Effects of catecholamines on regional perfusion and oxygenation in critically ill patients. Acta Anaesthesiol Scand Suppl 1995, 107:239-248.
9. Sun D, Huang A, Mital S, Kichuk MR, Marboe CC, Addonizio LJ, Michler RE, Koller A, Hintze TH, Kaley G: Norepinephrine elicits beta-2-receptor-mediated dilatation of isolated human coronary arterioles. Circulation 2002, 106:550-555.
10. Ahtee L, Michal F: Effects of sympathomimetic amines on rabbit platelet aggregation in vitro. Br J Pharmacol 1972, 44: 363-364.
11. Task Force of American College of Critical Care Medicine, Society of Critical Care Medicine: Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999, 3:639-660.
12. Cuche JL, Brochier P, Kliona N, Poirier ML: Conjugated catecholamines in human plasma: where are they coming from? J Lab Clin Med 1990, 116:681-686.
13. Le Corre P, Malledant Y, Tanguy M, Le Verge R: Steady-state pharmacokinetics of dopamine in adult patients. Crit Care Med 1993, 21:1652-1657.
14. Nagatsu T, Mogi M, Ichinose H, Togari A: Changes in cytokines and neutrophils in Parkinson's disease. J Neural Transm Suppl 2000, 60:277-290.
15. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ: Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation 2001, 15:544-549.
16. Berger SP, Hunger M, Yard BA, Schnuelle P, Van Der Woude FJ: Dopamine induces the expression of heme oxygenase-1 by human endothelial cells in vitro. Kidney Int 2000, 58:2314-2319.
17. Yard BA, Beck G, Schnülle P, Braun C, van der Woude FJ: Prevention of could preservation injury of cultured endothelial cells by catecholamines and related compounds. Am J Transplant 2003, 3:67-78.
18. Santambrogio L, Lipartiti M, Bruni A, Dal Toso R: Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol 1993, 45:113-119.
19. Emerson M, Paul W, Page CP: Regulation of platelet function by catecholamines in the cerebral vasculature of the rabbit. Br J Pharmacol 1999, 127:1652-1656.
20. Basic F, Uematsu S, McCarron RM, Spatz M: Dopaminergic receptors linked to adenylate cyclase in human cerebrovascular endothelium. J Neurochem 1991, 57:1774-1780.
21. Platzer C, Docke W, Volk H, Prosch S: Catecholamines trigger IL-10 release in acute systemic stress reaction by direct stimulation of its promoter/enhancer activity in monocytic cells. J Neuroimmunol 2000, 105:31-38.
22. Neumann M, Grieshammer T, Chuvpilo S, Kneitz B, Lohoff M, Schimpl A, Franza BR Jr, Serfling E: RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J 1995, 14:1991-2004.
23. Abraham E, Arcaroli J, Shenkar R: Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5′-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. J Immunol 2001, 166:522-530.
24. Basu S, Dasgupta PS: Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 2000, 102: 13-124.
25. Yang M, Zhang H, Voyno-Yasenetskaya T, Ye RD: Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation. Mol Pharmacol 2003, 64: 447-455.
26. Bergquist J, Ohlsson B, Tarkowski A: Nuclear factor kappa B is involved in the catecholaminergic suppression of immunocompetent cells. Ann NY Acad Sci 2000, 917:281-289.
27. Farmer P, Pugin J: β-adrenergic agonists exert their 'anti-inflammatory' effects in monocytic cells through the IκB /NF-κB pathway. Am J Physiol Lung Cell Mol Physiol 2000, 279: 675-L682.
28. Vogel CF, Sciullo E, Park S, Liedtke C, Trautwein C, Matsumura F: Dioxin increases C/EBPbeta transcription by activating cAMP/protein kinase A. J Biol Chem 2004, 279:8886-8894.
29. Brenner S, Prosch S, Schenke-Layland K, Riese U, Gausmann U, Platzer C: cAMP-induced interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J Biol Chem 2003, 278:5597-5604.
30. Inoue G: Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury. J Infect Chemother 2000, 6: 1-60.
31. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996, 97:713-719.
32. Weyler W, Hsu YP, Brakefield XO: Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 1990, 47:391-417.
33. 2 produced by monoamine oxidase. Kidney Int 2001, 59:76-86.
34. Chakraborti S, Chakraborti T: Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system. Cell Signal 1998, 10:675-683.
35. Gornekiewicz A, Sautner T, Brostjan C, Schmierer B, Fugger R, Roth E, Muhlbacher F, Bergamnn M: Catecholamines up-regulate LPS-induced IL-6 production in human microvascular endothelial cells. FASEB J 2000, 14:1093-1100.
36. Nappi AJ, Vass E, Prota G, Memoli S: The effects of hydroxylradical attack on dopa, dopamine 6-hydroxydopa and 6-hydroxydopamine. Pigment Cell 1995, 8:283-293.
37. Asanuma M, Miyazaki I, Ogawa N: Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003, 5:165-176.
38. Mattamal MB, Strong R, White VE, Hsu F: Characterisation of peroxidative oxidation products of dopamine by mass spectrometry. J Chromatog B 1994, 658:21-30.
39. Stokes A, Hastings TG, Vrana KE: Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55:659-665.
40. Van den Berghe G, de Zegher F, Bouillon R: Clinical review: acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998, 83:1827-1834.
41. Debaveye YA, van den Berghe GH: Is there still a place for dopamine in the modern intensive care unit? Anesth Analg 2004, 98:461-468.
42. Bendele AM, Spathe SM, Bensllay DN, Bryant HU: Anti-inflammatory activity of pergolide, a dopamine receptor agonist. J Pharmacol Exp Ther 1991, 259:169-175.
43. Zhu XH, Zellweger R, Wichmann MW, Ayala A, Chaudry IH: Effects of prolactin and metoclopramide on macrophage cytokine gene expression in late sepsis. Cytokine 1997, 9:437-446.
44. Zhu XH, Zellweger R, Ayala A, Chaudry IH: Prolactin inhibits the increased cytokine gene expression in Kupffer cells following haemorrhage. Cytokine 1996, 8:134-140.
45. Bernton EW, Meltzer MS, Holaday JW: Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science 1988, 239:401-404.
46. Bailey AR, Burchett KR: Effect of low-dose dopamine on serum concentrations of prolactin in critically ill patients. Br J Anaesth 1997, 78:97-99.
47. Beck GC, Oberacker R, Kapper S: Modulation of chemokine production in lung microvascular endothelial cells by dopamine is mediated via an oxidative mechanism. Am J Respir Cell Mol Biol 2001, 25:636-643.
48. Sookhai S, Wang JH, Winter D, Power C, Kirwan W, Redmond P: Dopamine attenuates the chemoattractant effect of interleukin-8: a novel role in the systemic inflammatory response syndrome. Shock 2000, 14:295-299.
49. Cosentino M, Marino F, Bombelli R: Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils. Life Sci 1999, 64:975-981.
50. Sookhai S, Wang JH, McCourt M, O'Connell D, Redmond HP: Dopamine induces neutrophil apoptosis through a dopamine D1 receptor independent mechanism. Surgery 1999, 126:314-322.
51. Burns AM, Keogan M, Donaldson M, Brown DL, Park GR: Effects of inotropes on human leucocyte numbers, neutrophil function and lymphocyte subtypes. Br J Anaesth 1997; 78:530-535.
52. Matsuoka T: Effects of dopamine on the respiratory burst in neonatal polymorphonuclear leukocytes. Pediatr Res 1990, 28:24-27.
53. Marino F, Cosentino M, Bombelli R, Ferrari M, Lecchini S, Frigo G: Endogenous catecholamine synthesis, metabolism storage, and uptake in human peripheral blood mononuclear cells. Exp Hematol 1999, 27:489-495.
54. Morikawa K, Oseko, F, Morikawa S: Immunosuppressive property of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 1993, 95:200-205.
55. Tarazona R, Gonzalez-Garcia A, Zamzami N, Marchetti P, Ruiz-Gajo M, von Rooijen N, Martinez C, Kroemer G: Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 1995, 154:861-870.
56. Hasko G, Szabo C, Nemeth Z, Deitch EA: Dopamine suppresses IL-12 p40 production by LPS-stimulated macrophages via β-adrenoreceptor-mediated mechanism. J Neuroimmunol 2002, 122:34-39.
57. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH: Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 1991, 104: 765-767.
58. Brown SW, Meyers RT, Brennan KM, Rumble JM, Narasimhachari N, Perozzi EF, Ryan JJ, Stewart JK, Fischer-Stenger K: Catecholamines in macrophage cell line. J Neuroimmunol 2003, 135:47-55.
59. Chi DS, Qui M, Krishnaswamy G, Li C, Stone W: Regulation of nitric oxide production from macrophages by LPS and catecholamines. Nitric Oxide 2003, 8:127-132.
60. Elenkov I, Chrousos GP: Stress hormones, proinflammatory and anti-inflammatory cytokines and autoimmunity. Ann NY Acad Sci 2002, 966:290-303.
61. LeFur G, Phan T, Uzan A: Identification of stereospecific 3H-spiroperidol binding sites in mammalian lymphocytes. Life Sci 1980, 26:1139-1148.
62. Morikawa K, Oseko, F, Morikawa S: Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 1994, 95:514-518.
63. Cook-Mills JM, Cohen RL, Perlman RL, Chambers DA: Inhibition of lymphocyte activation by catecholamines: evidence for a nonclassical mechanism of catecholamine action. Immunol 1995, 85:544-549.
64. Boukhris W, Kouassi E, Descotes J, Cordier G, Revillard JP: Impaired Z-dependent immune response in L-Dopa treated BALB/C mice. Clin Lab Immunol 1987, 23:185-189.
65. Tsao CW, Lin YS, Cheng JT: Effects of dopamine on immune cell proliferation in mice. Life Sci 1997, 61:PL361-PL371.
66. Mladenovic A, Perovic M, Raicevic N, Kanazir S, Rakic L, Ruzdijic S: 6-Hydroxydopamine increases the level of TNFalpha and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. Brain Res 2004, 23: 237-245.
67. Ziv I, Offen D, Haviv R, Stein R, Panet H, Zilkha-Falb R, Shirvan A, Barzilai A, Melamed E: The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease. Apoptosis 1997, 2:149-155.
68. Colombo C, Cosentino M, Marino F, Rasini E, Ossola M, Blandini F, Mangiagalli A, Samuele A, Ferrari M, Bombelli R, Lecchini S, Nappi G, Frigo G: Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells: possible relevance for Parkinson's disease. Ann N Y Acad Sci 2003, 1010: 679-682.
69. Hasko G: Receptor-mediated interaction between the sympathetic nervous system and immune system in inflammation. Neurochem Res 2001, 26:1039-1044.